⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2024

Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

Matthew T. Campbell Amishi Y. Shah Pavlos Msaouel Nizar M. Tannir Arlene O. Siefker‐Radtke Ashish M. Kamat Neema Navai Colin P. Dinney Priya Rao Charles C. Guo Rahul A. Sheth Aradhana M. Venkatesan Rebecca S. Tidwell Shalini S. Yadav Aidi Gu Hong Chen Marc Macaluso Fei Duan Sreyashi Basu Sonali Jindal Padmanee Sharma

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Treatment-related adverse events in the mRCC cohort

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Campbell et al. (2024) studied this question.

synapsesocial.com/papers/68e5833db6db643587520e3f https://doi.org/10.1158/2767-9764.27044484.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
2Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
3Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
4Table 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
5Table 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024

More related papers

Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024
Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer2024